T细胞大颗粒淋巴细胞白血病的临床结局:预后因素与治疗反应
该回顾性分析纳入60例连续T细胞大颗粒淋巴细胞白血病(T-LGLL)患者,评估临床病程与治疗反应。男性、乳酸脱氢酶升高及无类风湿关节炎者总生存受损。环磷酰胺(Cy)为最有效的二线药物,总缓解率70%(3例完全缓解、4例部分缓解),一线甲氨蝶呤(MTX)失败者均对二线Cy有反应。复发或Cy难治者中,阿仑单抗(n=4)与喷司他丁(n=3)总缓解率分别为50%和66%,duvelisib使1例获长期缓解。作者认为Cy是T-LGLL二线治疗的高效选择,并应考虑作为部分高危患者一线治疗的强候选方案。
要点
- 男性、乳酸脱氢酶升高及无类风湿关节炎的T-LGLL患者总生存受损。
- 环磷酰胺为最有效二线药物,总缓解率70%(3例完全缓解、4例部分缓解)。
- 所有一线甲氨蝶呤失败患者均对二线环磷酰胺有反应。
核心结论
- 作者认为环磷酰胺是T-LGLL二线治疗的高效药物,并应考虑作为部分高危患者一线治疗的强候选方案。
- 复发或难治性T-LGLL患者需前瞻性研究评估喷司他丁、阿仑单抗及duvelisib等新药。
研究设计与样本
- 回顾性分析纳入60例连续T-LGLL患者,评估临床病程与治疗反应。
主要发现
- 男性、乳酸脱氢酶升高及无类风湿关节炎的患者总生存受损。
- 环磷酰胺为最有效二线药物,总缓解率70%(3例完全缓解、4例部分缓解)。
- 所有一线甲氨蝶呤失败的患者均对二线环磷酰胺有反应。
- 复发或环磷酰胺难治者中,阿仑单抗(n=4)总缓解率50%,喷司他丁(n=3)总缓解率66%,duvelisib使1例获长期缓解。
关键数值与推荐
- 环磷酰胺二线治疗总缓解率70%,其中完全缓解3例、部分缓解4例。
- 阿仑单抗(n=4)总缓解率50%,喷司他丁(n=3)总缓解率66%。
临床怎么用
- 作者认为环磷酰胺是T-LGLL二线治疗的高效选择,并应考虑作为部分高危患者一线治疗的强候选方案。
- 作者建议对复发或难治性T-LGLL患者开展前瞻性研究评估喷司他丁、阿仑单抗及duvelisib等新药。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell large granular lymphocytic leukaemia (T-LGLL) is an incurable leukaemia characterised by clonal proliferation of abnormal cytotoxic T cells that can result in severe neutropenia, transfusion-dependent anaemia and pancytopenia requiring treatment. The most commonly used agents, methotrexate (MTX), cyclophosphamide (Cy) and cyclosporine primarily produce partial remissions (PRs), with few complete responses (CRs). We evaluated the clinical course and treatment response of 60 consecutive patients with T-LGLL to evaluate clinical outcomes and future potential treatment directions. Impaired overall survival was noted among male patients, patients with elevated lactate dehydrogenase, and those without rheumatoid arthritis. Cy was the most efficacious second-line agent, with a 70% overall response rate (ORR; three CR, four PR). All patients who failed frontline MTX responded to second-line Cy. In the relapsed or Cy-refractory setting, alemtuzumab (n = 4) and pentostatin (n = 3) had an ORR of 50% and 66%, respectively, while duvelisib induced a long-term response in one patient. In this large, retrospective analysis, our results suggest Cy is a highly effective therapy for second-line treatment in T-LGLL and should be considered a strong candidate for up-front therapy in select high-risk patients. Prospective studies evaluating pentostatin, alemtuzumab and novel agents, such as duvelisib, are needed for patients with relapsed/refractory T-LGLL.
引用
- Braunstein Z, Mishra A, Staub A, et al. Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response. Br J Haematol. 2020. PMID: 32519348. doi:10.1111/bjh.16808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。